May 31, 2015 | Oramed Pharmaceuticals, an Israeli company developing an insulin pill for diabetics, announced this week that it submitted a study protocol for its Phase IIb trials with the US Food & Drug Administration (FDA). The drug, tentatively named ORMD-0801 is an orally ingestible insulin capsule for the control and treatment of diabetes. It’s expected that the pill will change the face of current diabetes treatments. Oramed was founded in 2006 and is headquartered in Jerusalem.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023

Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments